Macro Dashboard
| Indicator | Level | 5-Day Δ | Signal |
|---|---|---|---|
| KOSPI | 6,820.6 | −8.8% | Bear |
| KOSDAQ | 791.8 | −5.4% | Bear |
| VIX | 18.1 | +5.4% | Stable |
| US 10Y | 4.57% | flat | Neutral |
| USD/KRW | 1,487 | −0.8% | KRW slight strength |
| Brent | $86.0 | +3.2% | Rising |
Regime verdict: KR Bear / US Neutral. KOSPI has shed 655 points over five sessions. KOSDAQ outperformed by 3.3 percentage points — a small-cap divergence consistent with selective, rather than systemic, selling. VIX at 18.1 is not alarming, which frames Korea’s weakness as local rather than global risk-off.
Market Wrap
No same-day KR close briefing (KR CLOSE BRIEFING or KR MARKET SNAPSHOT) was available for July 17. The following draws from macro-regime and derivatives flow data only.
The Bear-regime verdict on Korea is unambiguous. KOSPI at 6,820.6 and KOSDAQ at 791.8 are both in downtrend territory, but flow signals are nuanced. Derivatives basis closed at a positive +15.99 — futures at a premium to spot — which is not the signature of a forced liquidation. Net market program selling of −₩1.3 trillion was split −₩233bn (arbitrage) and −₩1.07 trillion (non-arbitrage), consistent with passive index mechanics rather than a directional conviction sell.
The more notable data point is ETF net creation of +₩3.5 trillion. Passive money is still entering the market via product wrappers even as active program flows run the other way. KOSDAQ’s relative resilience — outperforming KOSPI by 3.3pp over five sessions — hints at selective demand in mid- and small-cap names, which is consistent with what the meta-screener surfaces today: beauty ODM, diagnostics, and specialty semiconductor equipment.
Today’s Quality Re-Rating Candidates
Framework: Quality Compounder (QC) identifies compounding businesses; Smart Money Quality (SMQ) and Smart Money Earnings (SME) track institutional/foreign flow quality; Cycle Rerating (CR) catches operating leverage inflections; Consensus Up Revision (CUR) spots estimate upgrades; Kiwoom Market Surface (KMS) confirms today’s price/flow surface signal.
Top 10 Candidates
| Rank | Ticker | Name | Score | Signals | Key Metrics |
|---|---|---|---|---|---|
| 1 | 278470.KS | APR | 96.6 | QC · SMQ · SME · PEAD · CUR · KMS | ROE 65%, OP +198% YoY |
| 2 | 161890.KS | Korea Kolmar | 75.7 | QC · SMQ · SME · CR · KMS | ROE 14.7%, OP +24% YoY, margin +0.9pp |
| 3 | 096530.KQ | Seegene | 70.7 | QC · SMQ · SME · CR · KMS | ROE 4.8%, OP +310% YoY, margin +11.3pp |
| 4 | 420770.KQ | Gigavis | 65.7 | QC · CR · CUR · KMS | ROE 7.3%, OP +777% YoY, margin +29.9pp |
| 5 | 005935.KS | Samsung Elec. Pfd | 51.0 | QC · CR · KMS | ROE 10.8%, OP +33% YoY, margin +2.2pp |
| 6 | 089970.KQ | VM Co. | 49.6 | QC · CR · KMS | ROE 14.7%, OP +387% YoY, margin +29.3pp |
| 7 | 009150.KS | Samsung Electro-Mech. | 48.0 | QC · CR · KMS | ROE 7.4%, OP +24% YoY; 2 DART IR catalysts |
| 8 | 000660.KS | SK Hynix | 43.0 | QC · CR · KMS | ROE 35.6%, OP +101% YoY, margin +13.1pp |
| 9 | 319660.KQ | PSK | 40.7 | QC · KMS | ROE 15.5%, OP +5.5% YoY |
| 10 | 003490.KS | Korean Air | 37.6 | CUR · RS80 · KMS | Consensus z +1.02; active M&A filings |
Deep Dive: Top 3
#1 — APR (278470.KS) | Score 96.6 | Six Screeners
APR is a Korean direct-to-consumer beauty brand (Medicube) with an unusually high ROE of 65% and operating profit growth of +197.9% year-on-year — the strongest quality profile on today’s board. It is the only name hitting all five core screener layers simultaneously. On flows, foreign and quality-institutional buyers absorbed roughly ₩35.8bn of retail supply over five days (F+QI net +₩33.9bn). Two DART filings dated July 16 confirm a cash dividend declaration, adding near-term timing to the story. Check next: Whether quality-institutional sub-flow turns consistently positive; short interest at 6.5% with thin institutional coverage (#344 rank) can amplify volatility.
#2 — Korea Kolmar (161890.KS) | Score 75.7 | Five Screeners
Korea Kolmar is the country’s largest OEM/ODM cosmetics manufacturer, supplying formulas and packaging to both domestic and global beauty brands. Its case is more structural than APR: ROE 14.7%, operating profit +23.6% YoY, and a +0.9pp operating margin expansion that just cleared the Cycle Rerating threshold. Quality-institutional flow is net positive. A DART-filed IR meeting (July 6) signals management is actively engaging the buy-side. Check next: Whether the margin inflection is structural; short interest at 7.4% with a large borrow balance and foreign broker window selling are the main risk flags.
#3 — Seegene (096530.KQ) | Score 70.7 | Five Screeners
Seegene is Korea’s leading molecular diagnostics company, best known for its PCR multiplex technology. Post-COVID normalization crushed earnings; the re-rating thesis is about operating leverage recovering faster than the market has priced. Operating profit jumped +309.7% YoY, and the margin expanded +11.3pp — the largest margin inflection in the top three. F+QI absorbed ₩5bn in retail supply over five sessions. No DART filings in the recent lookback window, so the catalyst is purely earnings-driven. Check next: Whether the next earnings print confirms the margin recovery; short interest at 10.5% and a +24% ask-side premium in the order book signal elevated speculative positioning on both sides.
All data from July 17, 2026. Screener outputs are research candidates for further due diligence, not buy or sell recommendations.